Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2008 2
2009 3
2012 1
2013 1
2018 1
2019 7
2020 12
2021 10
2022 16
2023 12
2024 27
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline.
Davis MP, Davies A, McPherson ML, Reddy AS, Paice JA, Roeland EJ, Walsh D, Mercadante S, Case AA, Arnold RM, Satomi E, Crawford G, Bruera E, Bohlke K, Ripamonti C. Davis MP, et al. Among authors: satomi e. Support Care Cancer. 2025 Mar 3;33(3):243. doi: 10.1007/s00520-025-09286-z. Support Care Cancer. 2025. PMID: 40029420
Effects of enteral nutrition and parenteral nutrition on survival in patients with advanced cancer cachexia: Analysis of a multicenter prospective cohort study.
Amano K, Maeda I, Ishiki H, Miura T, Hatano Y, Tsukuura H, Taniyama T, Matsumoto Y, Matsuda Y, Kohara H, Morita T, Mori M; East-Asian collaborative cross-cultural Study to Elucidate the Dying process (EASED) Investigators. Amano K, et al. Clin Nutr. 2021 Mar;40(3):1168-1175. doi: 10.1016/j.clnu.2020.07.027. Epub 2020 Jul 31. Clin Nutr. 2021. PMID: 32771283
Dexamethasone for cancer-related dyspnoea.
Nishimura R, Ishiki H, Sato J, Satomi E. Nishimura R, et al. Among authors: satomi e. Lancet Oncol. 2022 Dec;23(12):e525. doi: 10.1016/S1470-2045(22)00657-X. Lancet Oncol. 2022. PMID: 36455574 No abstract available.
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.
Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K. Iihara H, et al. Among authors: satomi e. Int J Clin Oncol. 2024 Jul;29(7):873-888. doi: 10.1007/s10147-024-02535-x. Epub 2024 May 16. Int J Clin Oncol. 2024. PMID: 38753042 Free PMC article.
Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial.
Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S, Miyaji T, Mashiko T, Kobayashi N, Satomi E, Kiuchi D, Morita T, Uchitomi Y, Goto K, Ohe Y. Matsumoto Y, et al. Among authors: satomi e. Cancer Med. 2024 Nov;13(22):e70325. doi: 10.1002/cam4.70325. Cancer Med. 2024. PMID: 39556485 Free PMC article. Clinical Trial.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Nakashima K, Yokomizo A, Murakami M, Okita K, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Yamamoto N, Aogi K, Abe M. Nakashima K, et al. Among authors: satomi e. Int J Clin Oncol. 2024 Dec;29(12):1785-1794. doi: 10.1007/s10147-024-02643-8. Epub 2024 Oct 17. Int J Clin Oncol. 2024. PMID: 39417943
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H. Hayashi T, et al. Among authors: satomi e. Int J Clin Oncol. 2024 Nov;29(11):1616-1631. doi: 10.1007/s10147-024-02623-y. Epub 2024 Sep 11. Int J Clin Oncol. 2024. PMID: 39259324
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Murakami M, Miyata Y, Nakashima K, Abe M, Nishimura J, Wada M, Iino K, Akechi T, Iihara H, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Takeda M, Tanaka R, Nakamura N, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Nakajima TE. Murakami M, et al. Among authors: satomi e. Int J Clin Oncol. 2025 Jan;30(1):27-39. doi: 10.1007/s10147-024-02663-4. Epub 2024 Nov 21. Int J Clin Oncol. 2025. PMID: 39570460
84 results